阿托伐他汀联合依折麦布治疗冠状动脉支架植入术后低密度脂蛋白胆固醇未达标的效果分析  

Analysis of Effect of Atorvastatin Combined with Ezetimibe in Treatment of Substandard Low-Density Lipoprotein Cholesterol After Coronary Artery Stent Implantation

作　　者：张宁 Zhang Ning(Beijing Chaoyang District Futou Community Health Service Center,Beijing 100023,China)

机构地区：[1]北京市朝阳区垡头社区卫生服务中心,北京100023

出　　处：《中国社区医师》2025年第4期48-50,共3页Chinese Community Doctors

摘　　要：目的:探讨阿托伐他汀联合依折麦布治疗冠状动脉支架植入术后低密度脂蛋白胆固醇未达标的效果。方法:选取2023年6—9月于北京市朝阳区垡头社区卫生服务中心门诊就诊的冠状动脉支架植入术后低密度脂蛋白胆固醇未达标的80例患者进行研究,依据随机数字表法分为两组,每组40例。对照组采用阿托伐他汀治疗。研究组采用阿托伐他汀联合依折麦布治疗。对比两组患者血脂水平、低密度脂蛋白胆固醇达标情况及不良反应发生率。结果:治疗前,两组总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯水平比较,差异无统计学意义(P>0.05)。治疗后,两组总胆固醇、低密度脂蛋白胆固醇、甘油三酯水平下降,且研究组低于对照组(P<0.05);两组高密度脂蛋白胆固醇水平升高,且研究组高于对照组(P<0.05)。研究组低密度脂蛋白胆固醇达标率较对照组高(P=0.003)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀联合依折麦布治疗冠状动脉支架植入术后低密度脂蛋白胆固醇未达标的效果较好,可改善患者血脂水平,提高低密度脂蛋白胆固醇达标率,且不会增加不良反应。Objective:To explore the effect of atorvastatin combined with ezetimibe in treatment of substandard low-density lipo⁃protein cholesterol after coronary artery stent implantation.Methods:From June 2023 to September 2023,80 patients with substan⁃dard low-density lipoprotein cholesterol after coronary artery stent implantation who were admitted to the clinic of Beijing Chaoy⁃ang District Futou Community Health Service Center were selected for study.According to the random number table method,they were divided into two groups with 40 cases in each group.The control group was treated with atorvastatin.The study group was treated with atorvastatin and ezetimibe.The blood lipid levels,the compliance status of low-density lipoprotein cholesterol and the incidence of adverse reactions were compared between the two groups.Results:Before treatment,there was no statistically signifi⁃cant difference in the levels of total cholesterol,low-density lipoprotein cholesterol,high-density lipoprotein cholesterol and tri⁃glycerides between the two groups(P>0.05).After treatment,the levels of total cholesterol,low-density lipoprotein cholesterol and triglycerides in the two groups decreased,and the levels in the study group were lower than those in the control group(P<0.05).The levels of high-density lipoprotein cholesterol in the two groups increased and the levels in the study group were higher than those in the control group(P<0.05).The compliance rate of low-density lipoprotein cholesterol in the study group was higher than that in the control group(P=0.003).There was no statistically significant difference in the total incidence of adverse reactions be⁃tween the two groups(P>0.05).Conclusion:Atorvastatin combined with ezetimibe has good effects in treatment of substandard low-density lipoprotein cholesterol after coronary artery stent implantation,and can improve the patient's blood lipid levels,in⁃crease the compliance rate of low-density lipoprotein cholesterol,and will not increase adverse reactions.

关 键 词：阿托伐他汀 依折麦布 冠状动脉支架植入术 低密度脂蛋白胆固醇 

分 类 号：R541.4[医药卫生—心血管疾病]